Anti-CGRP for Inflamation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test a migraine medication on people with nerve pain to see if it reduces their pain and need for other painkillers. The study will also check if the medication is safe for these people.
Will I have to stop taking my current medications?
The trial aims to reduce the use of rescue and other anti-pain medications, but it does not specify if you must stop taking your current medications. It's best to discuss this with the trial coordinators.
What is known about the safety of Galcanezumab (Emgality) in humans?
How is the drug Galcanezumab different from other treatments?
Galcanezumab is unique because it specifically targets and blocks a protein called calcitonin gene-related peptide (CGRP), which is involved in causing migraines. This mechanism of action is different from traditional migraine treatments that often focus on relieving symptoms rather than preventing them.678910
Who Is on the Research Team?
Sweta Sengupta, MD
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Galcanezumab injections on Day 30, Day 60, and Day 90
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Galcanezumab
Galcanezumab is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Eli Lilly and Company
Industry Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University